概要

In September 2024, the Hong Kong Monetary Authority (HKMA) and the Securities and Futures Commission (SFC) issued their conclusions on the joint further consultation paper on enhancements to the OTC derivatives reporting regime for Hong Kong to mandate the use of Unique Transaction Identifiers (UTIs), Unique Product Identifiers (UPIs), the reporting of Critical Data Elements (CDEs) and the adoption of the ISO 20022 XML standard.

The scale and complexity of these changes present a significant challenge for reporting entities, who are required to implement the new requirements by 29 September 2025. It is therefore crucial for firms to take immediate action to prepare for the expanded reporting scope, understand the intricate data requirements and allocate resources to update their systems and processes as soon as possible.

內容

They key topics to be covered include:

• Overview of the key changes to the Hong Kong OTC derivatives reporting regime
• Key implications for firms
• Industry insights and views of peer practices
• Areas of uncertainty and how to navigate key risks and challenges
• Implementation timeline and immediate steps firms should be taking

對象

• Operations and technology functions involved in implementing the new OTC reporting requirements
• Senior management and compliance functions responsible for overseeing and monitoring their firm’s OTC trade reporting processes and controls